What do systematic reviews say?

Platinum‐containing chemotherapy vs chemotherapy without platinum

Platinum‐containing chemotherapy leads to lower OS at 2 years compared with chemotherapy without platinum (high certainty).

• Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
  HR 0.7 [0.5, 0.96]
  4 studies · 1256 participants
  High

Platinum‐containing chemotherapy vs chemotherapy without platinum

Platinum‐containing chemotherapy leads to lower OS at 5 years compared with chemotherapy without platinum (high certainty).

• Platinum‐based chemotherapy for early triple‐negative breast cancer 2023 · Cochrane Headline outcomes only
  HR 0.7 [0.5, 0.96]
  4 studies · 1256 participants
  High

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 183 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

Summary of findings table ‐ Systemic therapy showed no clear difference in change in grip strength from baseline to end of intervention compared with control (low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 1.08 [0.37, 3.17]
  1 study · 137 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 344 participants
  Very low

Summary of findings table ‐ Systemic therapy vs control

Summary of findings table ‐ Systemic therapy showed no clear difference in effect on discontinuation of aromatase inhibitors (AI) compared with control (low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 0.16 [0.01, 2.99]
  1 study · 147 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 44 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1 participants
  Low

Summary of findings table ‐ Systemic therapy vs control

It is very uncertain whether summary of findings table ‐ Systemic therapy changes incidence of AIMSS compared with control (very low certainty).

• Systemic therapies for preventing or treating aromatase inhibitor‐induced musculoskeletal symptoms in early breast… 2022 · Cochrane Headline outcomes only
  RR 0.82 [0.63, 1.06]
  2 studies · 240 participants
  Very low

OFS vs no OFS

OFS leads to lower overall survival (OS) Median compared with no OFS (high certainty).

• Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer 2020 · Cochrane Headline outcomes only
  HR 0.86 [0.78, 0.94]
  11 studies · 10374 participants
  High

OFS vs no OFS

OFS leads to lower disease‐free survival (DFS) Median compared with no OFS (high certainty).

• Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer 2020 · Cochrane Headline outcomes only
  HR 0.83 [0.77, 0.9]
  10 studies · 8899 participants
  High

OFS vs no OFS

OFS may leads to higher toxicity ‐ hot flushes (a combination of "grade 3/4" and "any grade"… compared with no OFS (low certainty).

• Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer 2020 · Cochrane Headline outcomes only
  RR 1.6 [1.41, 1.82]
  6 studies · 5581 participants
  Low

OFS vs no OFS

• Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer 2020 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 5354 participants
  Moderate

OFS vs no OFS

OFS may leads to higher toxicity ‐ bone health (osteoporosis defined by a T score < ‐2.5) compared with no OFS (low certainty).

• Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer 2020 · Cochrane Headline outcomes only
  RR 1.66 [1.1, 2.5]
  1 study · 2011 participants
  Low

OFS vs no OFS

OFS probably leads to lower contralateral breast cancer compared with no OFS (moderate certainty).

• Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer 2020 · Cochrane Headline outcomes only
  RR 0.75 [0.57, 0.97]
  8 studies · 7856 participants
  Moderate

OFS vs no OFS

• Ovarian suppression for adjuvant treatment of hormone receptor‐positive early breast cancer 2020 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 2996 participants
  Low

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Taxane‐containing chemotherapy leads to lower overall survival compared with any chemotherapy without taxane (high certainty).

• Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
  HR 0.87 [0.83, 0.92]
  27 studies · 39180 participants
  High

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Taxane‐containing chemotherapy leads to lower disease‐free progression compared with any chemotherapy without taxane (high certainty).

• Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
  HR 0.88 [0.85, 0.92]
  29 studies · 41909 participants
  High

Taxane‐containing chemotherapy vs any chemotherapy without taxane

• Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 7 participants
  Low

Taxane‐containing chemotherapy vs any chemotherapy without taxane

Taxane‐containing chemotherapy showed no clear difference in febrile neutropenia compared with any chemotherapy without taxane (moderate certainty).

• Taxanes for adjuvant treatment of early breast cancer 2019 · Cochrane Headline outcomes only
  OR 1.43 [0.89, 2.31]
  23 studies · 34154 participants
  Moderate